Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.45 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.45 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.45 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18628997 | 1.00 | POLB (0.53) | POLBSLC6A3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL17518655 | 1.00 | POLB (0.53) | POLBSLC6A3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL34462074 | 1.00 | POLB (0.53) | POLBSLC6A3KCNQ3KCNQ2KCNQ4 | |
| SCHEMBL9967101 | 0.89 | CHRM2 (0.42) | POLBSLC6A3SLC6A4 | |
| SCHEMBL18913409 | 0.89 | CHRM2 (0.42) | POLBSLC6A3SLC6A4 | |
| SCHEMBL5422531 | 0.89 | CHRM2 (0.42) | POLBSLC6A3SLC6A4 | |
| Hydrochloric Acid SCHEMBL4386858 | 0.88 | SLC6A3 (0.41) | POLBSLC6A3SLC6A4 | |
| SCHEMBL17243890 | 0.87 | CHRM2 (0.46) | SLC6A3TSHRMEN1KMT2A | |
| SCHEMBL7647666 | 0.83 | POLB (0.52) | POLBKCNQ3KCNQ2KCNQ4KCNQ5 | |
| SCHEMBL2515949 | 0.83 | POLB (0.52) | POLBKCNQ3KCNQ2KCNQ4KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090509-A1 | SPIRO HETEROCYCLIC CDK2 INHIBITORS | ARCHITECT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | OSMO LABS PBC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025031481-A1 | RXFP1 RECEPTOR MODULATOR AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-02-13 | — | — | WO | disclosed |
| US-20230359119-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| CN-116903791-A | Hydrocarbon resin polymer, method for preparing the same, composition comprising the same, and substrate | 李长荣化学工业股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3514221-B1 | USE AS A PERFUME MATERIAL | MITSUBISHI GAS CHEMICAL CO (JP) | 2022-01-19 | — | — | EP | disclosed |
| EP-3427738-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10988491-B2 | Degradable polymers of a cyclic silyl ether and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-04-27 | — | — | US | disclosed |
| US-10858367-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200283696-A1 | PERFUME COMPOSITION | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2020-09-10 | — | — | US | disclosed |
| CN-1576272-A | Sulfonate and a resist composition | SUMITOMO CHEMICAL CO (JP) | 2005-02-09 | — | — | CN | disclosed |
| CN-1527808-A | Process for production of fluorine-containing norbornene derivatives | ͬ�Ϳ�ҵ��ʽ���� | 2004-09-08 | — | — | CN | disclosed |
| EP-1230241-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2002-08-14 | — | — | EP | disclosed |
| CN-1347939-A | Cycloolefen addition copolymer composition and cross-linked material | JSR CORP (JP) | 2002-05-08 | — | — | CN | disclosed |
| WO-2001034604-A2 | ADENOSINE RECEPTOR ANTAGONISTS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| CN-1190410-A | Addition polymers of polycycloolefines containing functional substituents | GOODRICH CO B F (US) | 1998-08-12 | — | — | CN | disclosed |
| EP-0402881-B1 | Process for improving the coefficient of traction. | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| US-5126065-A | PROCESS FOR IMPROVING THE COEFFICIENT OF TRACTION AND TRACTION DRIVE FLUID | IDEMITSU KOSAN CO., LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0402881-A1 | Process for improving the coefficient of traction. | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-12-19 | — | — | EP | disclosed |
| US-3965132-A | DIMERS FROM OLEFINS AND WATER OR ALCOHOL AND CARBON MONOXIDE, TRIFLUOROMETHANESULFONIC ACID | PHILLIPS PETROLEUM COMPANY (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858367-B2 | Compounds | LRRK2, PARK7, PINK1 | POLB 1001/4885SLC6A3 2528/4885KCNQ3 3057/4885 |
| US-10988491-B2 | Degradable polymers of a cyclic silyl ether and uses thereof | SI, ILK, PCNA | POLB 670/4885SLC6A3 4796/4885KCNQ3 4864/4885 |
| US-20200283696-A1 | PERFUME COMPOSITION | H1-0, H1-2, CUTA | POLB 152/4885SLC6A3 4649/4885KCNQ3 685/4885 |
| US-20260078079-A1 | FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING NORBORNANE AND NORBORNENE DERIVATIVES | CBR1, CBR3, TAS2R1 | POLB 1910/4885SLC6A3 4858/4885KCNQ3 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.